Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Rating of “Moderate Buy” by Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $19.00.

A number of equities research analysts recently issued reports on FULC shares. JPMorgan Chase & Co. started coverage on Fulcrum Therapeutics in a research note on Monday, January 12th. They issued an “overweight” rating and a $20.00 price objective on the stock. Leerink Partners reiterated an “outperform” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Truist Financial set a $17.00 price target on Fulcrum Therapeutics in a research report on Tuesday, February 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, April 21st. Finally, Wall Street Zen upgraded Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday.

Institutional Investors Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Fulcrum Therapeutics during the fourth quarter valued at about $30,000. Quarry LP bought a new stake in shares of Fulcrum Therapeutics during the third quarter valued at about $35,000. Meeder Asset Management Inc. bought a new stake in shares of Fulcrum Therapeutics during the fourth quarter valued at about $39,000. Summit Securities Group LLC bought a new stake in shares of Fulcrum Therapeutics during the first quarter valued at about $53,000. Finally, Russell Investments Group Ltd. increased its position in shares of Fulcrum Therapeutics by 4,209.3% during the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after buying an additional 9,092 shares during the period. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Stock Performance

Shares of Fulcrum Therapeutics stock opened at $7.02 on Wednesday. Fulcrum Therapeutics has a 52-week low of $4.78 and a 52-week high of $15.74. The stock’s 50-day simple moving average is $7.75 and its 200 day simple moving average is $9.50. The stock has a market capitalization of $467.74 million, a P/E ratio of -6.10 and a beta of 3.02.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.06. Equities research analysts forecast that Fulcrum Therapeutics will post -1.18 EPS for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.